Background The atrium is the major site of ANP synthesis, which has been said to increase in heart failure as a result of increased production in the left ventricular (LV) myocardium. This is a key issue related to its diagnostic and prognostic capabilities. We aimed to evaluate protein levels of proANP and ANP and the enzymes that cleave the natriuretic peptides, corin and furin, in the LV tissue of heart transplant patients with dilated (DCM) and ischemic (ICM) cardiomyopathy compared with control donors (CNT). We also evaluate mRNA levels of ANP gene (NPPA) by RNA sequencing in the same tissue. Methods and Results Seventy-three human LV tissue samples from ICM (n = 30) and DCM (n = 33) patients and CNT (n = 10) were analyzed by Western blot and RNA sequencing. Comparing protein levels according to etiology, neither DCM nor ICM showed levels of proANP or ANP different from those of CNT. However, NPPA was increased in both groups compared to CNT (DCM 32 fold, p<0.0001; ICM 10 fold, p<0.0001). Corin (but not furin) was elevated in the ICM group compared to CNT (112±24 vs. 100±7, p<0.05), and its level was inversely related with LV ejection fraction (LVEF) (r = ？0.399, p<0.05). Conclusions Patients present with elevated levels of NPPA but not of proANP or ANP proteins in LV tissue, which may be due to posttranscripcional regulation of NPPA or different pathways for ANP secretion between the atrium and ventricle. Moreover, there are differences between DCM and ICM in corin levels, indicating that a different molecular mechanism may exist that converge in this syndrome. Further, LV concentration of corin is inversely related to LVEF in ICM.
References
[1]
Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardio protection. Cardiovasc Res 69: 318–328. doi: 10.1016/j.cardiores.2005.10.001
[2]
Rivera M, Cortés R, Salvador A, Bertomeu V, de Burgos FG, et al. (2005) Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology. Eur J Heart Fail 7: 1168–1170. doi: 10.1016/j.ejheart.2005.04.003
[3]
Cortés R, Portolés M, Salvador A, Bertomeu V, García de Burgos F, et al. (2006) Diagnostic and prognostic value of urine NT-proBNP levels in heart failure patients. Eur J Heart Fail 8: 621–627. doi: 10.1016/j.ejheart.2005.11.011
[4]
Cortés R, Rivera M, Salvador A, Bertomeu V, de Burgos FG, et al. (2007) Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study. Heart 93: 957–962. doi: 10.1136/hrt.2006.096891
[5]
Cortés R, Roselló-Lletí E, Rivera M, Martínez-Dolz L, Salvador A, et al. (2011) Expression of B-type natriuretic peptide forms in ischemic human hearts. Int J Cardiol 158: 199–204. doi: 10.1016/j.ijcard.2011.01.014
[6]
Roselló-Lletí E, Calabuig JR, Morillas P, Cortés R, Martínez-Dolz L, et al. (2012) Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study. PLoS One 7: e31189. doi: 10.1371/journal.pone.0031189
[7]
Seronde MF, Gayat E, Logeart D, Lassus J, Laribi S, et al. (2013) Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol 168: 3404–3411. doi: 10.1016/j.ijcard.2013.04.164
[8]
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388–2442. doi: 10.1093/eurheartj/ehn528
[9]
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154–235. doi: 10.1161/circulationaha.105.167586
[10]
Liu P, Arnold JM, Belenkie I, Demers C, Dorian P, et al. (2003) The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol 19: 347–356.
[11]
Ruskoaho H (2003) Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 24: 341–356. doi: 10.1210/er.2003-0006
[12]
Wu Q, Xu-Cai YO, Chen S, Wang W (2009) Corin: new insights into the natriuretic peptide system. Kidney Int 75: 142–146. doi: 10.1038/ki.2008.418
[13]
Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, et al. (2010) Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 56: 1166–1176. doi: 10.1373/clinchem.2010.143883
[14]
Dong N, Chen S, Yang J, He L, Liu P, et al. (2010) Plasma soluble corin in patients with heart failure. Circ Heart Fail 3: 207–211. doi: 10.1161/circheartfailure.109.903849
[15]
Ichiki T, Boerrigter G, Huntley BK, Sangaralingham SJ, Mckie PM, et al. (2013) Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol 304: R102–109. doi: 10.1152/ajpregu.00233.2012
[16]
Tsuchimochi H, Kurimoto F, Ieki K, Kayama H, Takaku F, et al. (1998) Atrial natriuretic peptide distribution in fetal and failed adult human hearts. Circulation 78: 920–927. doi: 10.1161/01.cir.78.4.920
[17]
Macrae DJ (2007) The Council for International Organizations and Medical Sciences (CIOMS) guidelines on ethics of clinical trials. Proc Am Thorac Soc 4: 176–178. doi: 10.1513/pats.200701-011gc
[18]
Tarazón E, Rivera M, Roselló-Lletí E, Molina-Navarro MM, Sánchez-Lázaro IJ, et al. (2012) Heart failure induces significant changes in nuclear pore complex of human cardiomyocytes. PLoS One 7: e48957. doi: 10.1371/journal.pone.0048957
[19]
Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, et al. (2010) 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 12: 1143–1153. doi: 10.1093/europace/euq392
[20]
Winters AL, Minchin FR (2005) Modification of the Lowry assay to measure proteins and phenols in covalently bound complexes. Anal Biochem 346: 43–48. doi: 10.1016/j.ab.2005.07.041
[21]
Li H, Handsaker B, Wysoker A, Fenell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078–2079. doi: 10.1093/bioinformatics/btp352
[22]
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297–1303. doi: 10.1101/gr.107524.110
[23]
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511–515. doi: 10.1038/nbt.1621
[24]
Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11: R106. doi: 10.1186/gb-2010-11-10-r106
[25]
Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139–140. doi: 10.1093/bioinformatics/btp616
[26]
Saito Y, Nakao K, Arai H, Sagawara A, Morii N, et al. (1987) Atrial natriuretic polypeptide (ANP) in human ventricle. Increased gene expression of ANP in dilated cardiomyopathy. Biochem Biophys Res Commun 148: 211–217. doi: 10.1016/0006-291x(87)91097-7
[27]
Takahashi T, Allen PD, Izumo S (1992) Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene. Circ Res 71: 9–17. doi: 10.1161/01.res.71.1.9
Nelesen RA, Dimsdale JE, Ziegler MG (1992) Plasma atrial natriuretic peptide is unstable under most storage conditions. Circulation 86: 463–466. doi: 10.1161/01.cir.86.2.463
[30]
Miao L, Wang M, Yin WX, Yuan Q, Chen YX, et al. (2010) Atrial natriuretic peptide regulates Ca channel in early developmental cardiomyocytes. PLoS One 5: e8847. doi: 10.1371/journal.pone.0008847
[31]
Bloch KD, Seidman JG, Naftilan JD, Fallon JT, Seidman CE (1986) Neonatal atria and ventricles secrete atrial natriuretic factor via tissue-specific secretory pathways. Cell 47: 695–702. doi: 10.1016/0092-8674(86)90512-x
[32]
Ibebuogu UN, Gladysheva IP, Houng AK, Reed GL (2011) Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail 4: 114–120. doi: 10.1161/circheartfailure.109.895581
[33]
Mooney M, Bond J, Monks N, Eugster E, Cherba D, et al. (2013) Comparative RNA-Seq and microarray analysis of gene expression changes in Bcell lymphomas of Canis familiaris. PLoS One 8: e61088. doi: 10.1371/journal.pone.0061088
[34]
Arora P, Wu C, Khan AM, Bloch DB, Davis-Dusenbery BN, et al. (2013) Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest 123: 3378–3382. doi: 10.1172/jci67383
[35]
Waldo SW, Beede J, Isakson S, Villard-Saussine S, Fareh J, et al. (2008) Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 51: 1874–1882. doi: 10.1016/j.jacc.2007.12.051
[36]
Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35: 569–582. doi: 10.1016/s0735-1097(99)00630-0
